MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Trade accountsreceivable-$11,920K Noncash interestexpense$614K Inventory write-down forexcess & obsolescence$192K Change in fair value offinancial instruments-$162K Amortization of intangibleasset$75K Loss on contingentliability$58K Noncash right-of-useasset amortization$32K Stock-based compensation$15K Depreciation$4K Net cash and cashequivalents and net...$2,301K Canceled cashflow$10,771K Net change in cashand cash...$1,801K Canceled cashflow$500K Net income (loss)-$5,465K Accrued expenses andother liabilities-$1,636K Accounts payable-$1,605K Accrued compensation-$1,092K Inventories$761K Prepaid and other assets$130K Contingent liabilities-$50K Operating leaseliabilities-$32K Net cash and cashequivalents and net...-$498K Net cash and cashequivalents and net...-$2K Payments under short termdebt and notes ...$498K Purchases of property andequipment$2K
Cash Flow

Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. (EVFM)

source: myfinsight.com